Quantcast

HPV Vaccine Vs. HPV Infection in Men

February 3, 2011

(Ivanhoe Newswire) — Infection with human papillomavirus (HPV) and diseases caused by HPV are common in boys and men.   A new report shows the safety of a quadrivalent vaccine and on its efficacy in preventing the development of external genital lesions and anogenital HPV infection in boys and men.

Study authors enrolled 4065 healthy boys and men 16 to 26 years of age, from 18 countries in a randomized, placebo-controlled, double-blind trial. The primary efficacy objective was to show that the quadrivalent HPV vaccine reduced the incidence of external genital lesions related to HPV-6, 11, 16, or 18. Efficacy analyses were conducted in a per-protocol population, in which subjects received all three vaccinations and were negative for relevant HPV types at enrollment, and in an intention-to-treat population, in which subjects received vaccine or placebo, regardless of baseline HPV status.

In the intention-to-treat population, 36 external genital lesions were seen in the vaccine group as compared with 89 in the placebo group, for an observed efficacy of 60.2%; the efficacy was 65.5% for lesions related to HPV-6, 11, 16, or 18. In the per-protocol population, efficacy against lesions related to HPV-6, 11, 16, or 18 was 90.4%.

Efficacy with respect to persistent infection with HPV-6, 11, 16, or 18 and detection of related DNA at any time was 47.8% and 27.1%, respectively, in the intention-to-treat population and 85.6% and 44.7% in the per-protocol population. Injection-site pain was significantly more frequent among subjects receiving quadrivalent HPV vaccine than among those receiving placebo.

Quadrivalent HPV vaccine prevents infection with HPV-6, 11, 16, and 18 and the development of related external genital lesions in males 16 to 26 years of age.

SOURCE: The New England Journal Of Medicine, published online February 2011




comments powered by Disqus